Shots:

• The companies collaborated to evaluate XTX101 + Keytruda for patients with solid tumors. The planned P-I study will be conducted by Xilio and is designed to evaluate the safety & efficacy of XTX101 as a monothx. and in combination with Keytruda for solid tumors
• Xilio plans to submit an IND for XTX101 to the US FDA in Q2’21. Following the IND clearance- Xilio expects to initiate a P-I study. In preclinical studies- XTX101 was well-tolerated and achieved robust tumor growth inhibition
• XTX101 is a tumor-selective anti-CTLA-4 mAb designed to pinpoint the anti-CTLA-4 effect geographically within the tumor without off-tumor peripheral effects

  Ref: Businesswire | Image: Merck